# Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography

Study · id `cardio:ct-nct06520904` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06520904](<https://clinicaltrials.gov/study/NCT06520904>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06520904

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 396 participants.

## Technical summary

Registry record NCT06520904. Randomized; no masking; primary purpose treatment. Start 2024-07-01 (actual); primary completion 2026-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 396 participants (planned count; ClinicalTrials.gov record NCT06520904, source copy `cardio:ctgov-nct06520904-2024-08-19`, retrieved 2026-10-26)
- Started: 2024-07-01 (actual) (ClinicalTrials.gov record NCT06520904, source copy `cardio:ctgov-nct06520904-2024-08-19`, retrieved 2026-10-26)
- Primary completion: 2026-09-30 (anticipated) (ClinicalTrials.gov record NCT06520904, source copy `cardio:ctgov-nct06520904-2024-08-19`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06520904, source copy `cardio:ctgov-nct06520904-2024-08-19`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06520904, source copy `cardio:ctgov-nct06520904-2024-08-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06520904-2024-08-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography
- Condition: Coronary Artery Disease
- Condition: Optical Coherence Tomography
- Intervention (Drug): PCSK9 inhibitor
- Intervention (Drug): Statin
- Lead sponsor: First Affiliated Hospital of Xinjiang Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: First Affiliated Hospital of Xinjiang Medical University (`cardio:org-first-affiliated-hospital-of-xinjiang-medical-university`)

## Provenance

Content hash: c327d2399116e9eca7cc529b4c458adc69078161970ecbc9c0669ad693f21fbf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
